Sylentis S.A.U.

OKYO Pharma Limited is ready to move its dry eye disease candidate, OK-101, into Phase III and asserted that the efficacy and safety profile it has seen so far might position OK-101 to take a market-

At first glance, the curious thing about the failure of Sylentis S.A.U. ’s tivanisiran in a Phase III trial in dry-eye disease associated with Sjögren’s syndrome is that it follows a late-stage hit i

HanAll BioPharma Co. Ltd. and Daewoong Pharmaceutical Co. Ltd. have unveiled top-line results from the first US Phase III study for HL036, their investigational biologic for the treatment of dry ey

ReGenTree LLC has announced mixed results from the second pivotal Phase III clinical trial (ARISE-2) in the US of RGN-259 for the treatment of dry eye. RGN-259’s global effects on dry eye syndrome a